GRI Bio wins FDA orphan drug designation for GRI-0621 in pulmonary fibrosis

GRI Bio

GRI Bio

GRI

0.00
  • FDA granted orphan drug designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis.
  • Designation could support 7 years of US market exclusivity if the drug wins approval.
  • GRI-0621 is a once-daily oral RARβ/γ-selective agonist evaluated in a Phase 2a trial in 35 patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180831PRIMZONEFULLFEED9748992) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.